![[up]](/style/images/multi_up.png)
Up a levelGroup by: Item Type | Date
Jump to: Journal article
Number of items: 3.
Journal article
Schoffski, Patrick; Kubickova, Michaela; Wozniak, Agnieszka; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Switaj, Tomasz; Bucklein, Veit; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Lee, Che-Jui; Speetjens, Frank M.; Nzokirantevye, Axelle; Neven, Anouk und Kasper, Bernd
(2021):
Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
In: European Journal of Cancer, Vol. 156: pp. 12-23
Ray-Coquard, Isabelle; Hatcher, Helen; Bompas, Emmanuelle; Casado, Antonio; Westermann, Annekke; Isambert, Nicolas; Casali, Paolo Giovanni; Pratap, Sarah; Stark, Daniel; Valverde, Claudia; Anand, Anjana; Huizing, Manon; Floquet, Anne; Lindner, Lars; Hermes, Barbara; Seddon, Beatrice; Coens, Corneel; Jones, Robin und Reed, Nick
(2020):
A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high-grade uterine sarcoma after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment (EORTC62113).
In: International Journal of Gynecological Cancer, Vol. 30, No. 10: pp. 1633-1637
Schoffski, Patrick; Sufliarsky, Jozef; Gelderblom, Hans; Blay, Jean-Yves; Strauss, Sandra J.; Stacchiotti, Silvia; Rutkowski, Piotr; Lindner, Lars H.; Leahy, Michael G.; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Cann, Thomas van; Marreaud, Sandrine; Nzokirantevye, Axelle; Collette, Sandra und Wozniak, Agnieszka
(2018):
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
In: Lancet Respiratory Medicine, Vol. 6, No. 6: pp. 431-441